{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+%28TMZ%29&page=6", "query": { "intervention": "temozolomide (TMZ)", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 459, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+%28TMZ%29&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+%28TMZ%29&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T23:13:08.415Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06721689", "title": "PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Solid Tumors", "Relapsed Solid Tumors", "Relapsed Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Rhabdomyosarcoma", "Refractory Rhabdomyosarcoma" ], "interventions": [ { "name": "PEEL-224", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theodore Laetsch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 59, "start_date": "2025-03-23", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06721689" }, { "nct_id": "NCT03344250", "title": "Phase I EGFR BATs in Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "EGFR BATs with TMZ following SOC RT/TMZ", "type": "DRUG" }, { "name": "Weekly EGFR BATs following SOC RT/TMZ", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-03-01", "completion_date": "2023-05-08", "has_results": false, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03344250" }, { "nct_id": "NCT00003708", "title": "Chemotherapy in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "1998-07", "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2012-08-09", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 2, "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003708" }, { "nct_id": "NCT00612989", "title": "Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Temodar and O6-Benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-02", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612989" }, { "nct_id": "NCT03528642", "title": "Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytoma, IDH-Mutant, Grade 2", "Astrocytoma, IDH-Mutant, Grade 3" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Telaglenastat Hydrochloride", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 23, "start_date": "2019-05-01", "completion_date": "2027-09-18", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03528642" }, { "nct_id": "NCT03746080", "title": "Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma With Primitive Neuronal Component", "Gliosarcoma", "Malignant Glioma", "Oligodendroglial Component Present" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Whole-Brain Radiotherapy (WBRT)", "type": "RADIATION" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Lawrence D Recht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2018-12-04", "completion_date": "2024-02-08", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746080" }, { "nct_id": "NCT00376103", "title": "Radiation Boost for Newly Diagnosed Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "Brachytherapy", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Methodist Healthcare - Memphis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2006-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-09-18", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376103" }, { "nct_id": "NCT06528496", "title": "N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-risk Neuroblastoma", "Neuroblastoma", "Childhood Neuroblastoma" ], "interventions": [ { "name": "DANYELZA", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "19 Years", "sex": "ALL", "summary": "18 Months to 19 Years" }, "enrollment_count": 45, "start_date": "2024-07-22", "completion_date": "2029-07-22", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06528496" }, { "nct_id": "NCT00102648", "title": "Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Supratentorial Neoplasm", "Recurrent Glioblastoma", "Recurrent Gliosarcoma" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2004-12-21", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00102648" }, { "nct_id": "NCT05664243", "title": "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Autologous genetically modified gamma-delta T cells", "type": "BIOLOGICAL" }, { "name": "Allogeneic genetically modified gamma-delta T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "In8bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-09-08", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-10-07T23:13:08.415Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05664243" } ] }